$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420415037217 Filed on June 15, 2015

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$1.028M
YoY Change
Cost Of Revenue	$1.046M
YoY Change
Gross Profit	-$18.00K
YoY Change
Gross Profit Margin	-1.75%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$120.0K	$90.00K
YoY Change	33.33%	-25.0%
% of Gross Profit
Operating Expenses	$2.365M
YoY Change
Operating Profit	-$2.384M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$31.65M
YoY Change
Pretax Income
YoY Change
Income Tax	-$295.0K
% Of Pretax Income
Net Earnings	-$86.80M
YoY Change
Net Earnings / Revenue	-8443.39%
Basic Earnings Per Share	-$0.16
Diluted Earnings Per Share	-$0.16
COMMON SHARES
Basic Shares Outstanding	618.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.940M	$370.0K
YoY Change	1775.68%	-44.78%
Cash & Equivalents	$6.942M	$369.0K
Short-Term Investments
Other Short-Term Assets	$320.0K	$150.0K
YoY Change	113.33%	15.38%
Inventory	$1.932M	$1.358M
Prepaid Expenses
Receivables	$732.1K	$665.2K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.925M	$2.543M
YoY Change	290.22%	69.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.200M	$4.029M
YoY Change	4.24%	-5.87%
Goodwill
YoY Change
Intangibles	$6.350M	$694.4K
YoY Change	814.42%	8.02%
Long-Term Investments	$3.350M	$3.340M
YoY Change	0.3%	0.0%
Other Assets	$3.843M	$510.0K
YoY Change	653.61%	-5.56%
Total Long-Term Assets	$14.39M	$8.582M
YoY Change	67.72%	-2.59%
TOTAL ASSETS
Total Short-Term Assets	$9.925M	$2.543M
Total Long-Term Assets	$14.39M	$8.582M
Total Assets	$24.32M	$11.13M
YoY Change	118.58%	7.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.210M	$1.330M
YoY Change	66.17%	24.3%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$530.0K	$600.0K
YoY Change	-11.67%
Long-Term Debt Due	$87.57K	$3.390M
YoY Change	-97.42%	-0.29%
Total Short-Term Liabilities	$6.161M	$5.357M
YoY Change	15.0%	17.74%
LONG-TERM LIABILITIES
Long-Term Debt	$18.87K	$0.00
YoY Change
Other Long-Term Liabilities	$131.1K	$91.57K
YoY Change	43.22%	-99.56%
Total Long-Term Liabilities	$99.36M	$14.44M
YoY Change	587.99%	-30.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.161M	$5.357M
Total Long-Term Liabilities	$99.36M	$14.44M
Total Liabilities	$105.5M	$19.80M
YoY Change	432.95%	-21.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$225.0M	-$128.4M
YoY Change	75.2%
Common Stock	$144.1M	$120.1M
YoY Change	20.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares
Shareholders Equity	-$81.20M	-$8.673M
YoY Change
Total Liabilities & Shareholders Equity	$24.32M	$11.13M
YoY Change	118.58%	7.91%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$86.80M
YoY Change
Depreciation, Depletion And Amortization	$120.0K	$90.00K
YoY Change	33.33%	-25.0%
Cash From Operating Activities	-$1.480M	-$220.0K
YoY Change	572.73%	-155.0%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$20.00K
YoY Change	550.0%	-85.71%
Acquisitions
YoY Change
Other Investing Activities	$60.00K	$80.00K
YoY Change	-25.0%	300.0%
Cash From Investing Activities	-$70.00K	$60.00K
YoY Change	-216.67%	-150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.400M	480.0K
YoY Change	1441.67%	-352.63%
NET CHANGE
Cash From Operating Activities	-1.480M	-220.0K
Cash From Investing Activities	-70.00K	60.00K
Cash From Financing Activities	7.400M	480.0K
Net Change In Cash	5.850M	320.0K
YoY Change	1728.12%	255.56%
FREE CASH FLOW
Cash From Operating Activities	-$1.480M	-$220.0K
Capital Expenditures	-$130.0K	-$20.00K
Free Cash Flow	-$1.350M	-$200.0K
YoY Change	575.0%	-137.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6160824	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	732076	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	1932486	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	318424	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	9924763	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4199602	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6349922	USD
CY2014Q1	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	16314	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	265043	USD
CY2014Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	232756	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3843435	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	806019	USD
CY2014Q1	us-gaap	Assets Assets	24317722	USD
CY2014Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	18870	USD
CY2014Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	528750	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2214871	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5069097	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	138890	USD
CY2014Q1	eltp	Derivative Liability Preferred Shares DerivativeLiabilityPreferredShares	60981570	USD
CY2014Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	38103446	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272620	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5508377	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6074117	USD
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	560242430	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631160701	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	560142430	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	631060701	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	121697	USD
CY2015Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	135874	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134083	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1523341	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2850459	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	409146	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	58770	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	122772	USD
CY2014Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	107960	USD
CY2015Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	909477	USD
CY2015	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.057	pure
CY2015	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Maximum DebtInstrumentInterestRateStatedPercentageRateRangeMaximum	0.131	pure
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	104.242	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100	shares
CY2014Q1	eltp	Preferred Stock Conversion Shares PreferredStockConversionShares	148917143	shares
CY2015Q1	eltp	Preferred Stock Conversion Shares PreferredStockConversionShares	142857143	shares
CY2014Q1	eltp	Preferred Stock Closing Price PreferredStockClosingPrice	0.41
CY2015Q1	eltp	Preferred Stock Closing Price PreferredStockClosingPrice	0.245
CY2014Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	60981570	USD
CY2015Q1	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	35000000	USD
CY2015	us-gaap	Revenue Other Manufactured Products RevenueOtherManufacturedProducts	3870457	USD
CY2014	us-gaap	Contracts Revenue ContractsRevenue	82937	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	4601376	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	5015246	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	3236106	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	3013592	USD
CY2014	us-gaap	Gross Profit GrossProfit	1365270	USD
CY2015	us-gaap	Gross Profit GrossProfit	2001654	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3959316	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14727472	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82947	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	260045	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500906	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	616995	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	6648894	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	18508626	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-5283624	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-16506971	USD
CY2014	us-gaap	Interest Expense InterestExpense	859328	USD
CY2015	us-gaap	Interest Expense InterestExpense	287231	USD
CY2014	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	-32997869	USD
CY2015	eltp	Change In Fair Value Of Warrant Derivatives ChangeInFairValueOfWarrantDerivatives	18447573	USD
CY2014	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	-56518425	USD
CY2015	eltp	Change In Fair Value Of Preferred Share Derivatives ChangeInFairValueOfPreferredShareDerivatives	25602370	USD
CY2014	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	-1187879	USD
CY2015	eltp	Change In Fair Value Of Convertible Note Derivative Instruments ChangeInFairValueOfConvertibleNoteDerivativeInstruments	0	USD
CY2014	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	40588	USD
CY2015	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
CY2014	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2015	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670685	USD
CY2014	us-gaap	Other Income OtherIncome	19831	USD
CY2015	us-gaap	Other Income OtherIncome	0	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-91584258	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45433397	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96867882	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28926426	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-292611	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3248	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-96575271	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	463021991	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	591214959	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	463021991	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	757579152	shares
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-8673385	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	28929674	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13236624	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82947	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	260047	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	47987	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16365	USD
CY2014	eltp	Stockissuedduringperiodvaluepaymentofemployeesalaries Stockissuedduringperiodvaluepaymentofemployeesalaries	368233	USD
CY2015	eltp	Stockissuedduringperiodvaluepaymentofemployeesalaries Stockissuedduringperiodvaluepaymentofemployeesalaries	849737	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	453746	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	581855	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	68089	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest		USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	478233	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	959737	USD
CY2014	eltp	Interest Expense Non Cash InterestExpenseNonCash	568395	USD
CY2015	eltp	Interest Expense Non Cash InterestExpenseNonCash	0	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	82947	USD
CY2015	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	260047	USD
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1438	USD
CY2015	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1526	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66922	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	714365	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	574340	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1099518	USD
CY2014	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	169373	USD
CY2015	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	147188	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	883446	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1811258	USD
CY2014	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-13333	USD
CY2015	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-13333	USD
CY2014	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-27500	USD
CY2015	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4216875	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15103233	USD
CY2014	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	455323	USD
CY2015	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1545131	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	58178	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	31853	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2777	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	123916	USD
CY2014	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13236624	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	868050	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	800853	USD
CY2014	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	528750	USD
CY2015	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	54322	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1110000	USD
CY2014	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1515	USD
CY2015	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	219010	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47987	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16365	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
CY2014	us-gaap	Interest Paid InterestPaid	289494	USD
CY2015	us-gaap	Interest Paid InterestPaid	89336	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	3099	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11347299	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12746424	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6572754	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	522403	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	2500	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	107960	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	804861	USD
CY2014	eltp	Commitment Shares Issued CommitmentSharesIssued	1112838	USD
CY2015	eltp	Commitment Shares Issued CommitmentSharesIssued	830521	USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9825066	USD
CY2015	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2272500	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	5597317	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q3	dei	Entity Public Float EntityPublicFloat	153849213	USD
CY2015	dei	Trading Symbol TradingSymbol	ELTP
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	658419047	shares
CY2014	eltp	Stock Issued During Period Value Payment For Preferred Share Derivative Interest StockIssuedDuringPeriodValuePaymentForPreferredShareDerivativeInterest	68089	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9825066	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2272500	USD
CY2014	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	3601020	USD
CY2015	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	774853	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24300	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2014	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	110000	USD
CY2015	eltp	Stock Issued During Period Value Payment Of Directors Fees StockIssuedDuringPeriodValuePaymentOfDirectorsFees	110000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	18836	USD
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	23999	USD
CY2014	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	46945	USD
CY2015	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	419887	USD
CY2014	eltp	Stock Option Plan Expense1 StockOptionPlanExpense1	18836	USD
CY2015	eltp	Stock Option Plan Expense1 StockOptionPlanExpense1	23999	USD
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.9in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.9in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>NATURE OF BUSINESS</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.9in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Elite Pharmaceuticals, Inc. was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary Elite Laboratories, Inc. was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing and licensing proprietary controlled-release drug delivery systems and products. The Company is also equipped to manufacture controlled-release products on a contract basis for third parties and itself if and when the products are approved; however the Company has concentrated on developing orally administered controlled-release products. These products include drugs that cover therapeutic areas for pain, allergy and infection. The Company also engages in research and development activities for the purpose of obtaining Food and Drug Administration approval, and, thereafter, commercially exploiting generic and new controlled-release pharmaceutical products. The Company also engages in contract research and development on behalf of other pharmaceutical companies.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>CONCENTRATION OF CREDIT RISK</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains cash balances, which, at times, may exceed the amounts insured by the Federal Deposit Insurance Corp. Uninsured balances at March 31, 2015 are $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,464,180</font>. Management does not believe that there is any significant risk of losses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company in the normal course of business extends credit to its customers based on contract terms and performs ongoing credit evaluations. An allowance for doubtful accounts due to uncertainty of collection is established based on historical collection experience. Amounts are written off when payment is not received after exhaustive collection efforts. During Fiscal 2015 and Fiscal 2014 the Company generated all its revenues from seven and ten companies, respectively. The termination of the contracts with either of such companies will result in the loss of a significant amount of revenues currently being earned.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>USE OF ESTIMATES</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 66pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, the recognition of revenue, the amount of the allowance for doubtful accounts receivable and the fair value of intangible assets, stock-based awards and derivatives.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.9in"> <div><b>NOTE 25</b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b>CONTINGENCIES</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 63pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">As part of the Company’s efforts to ensure the retention and continuity of key employees, officers and directors in the event of a change of control of the ownership of the Company, the Board of Directors passed a resolution whereby, in the event of a change in control of the ownership of the Company, key executives would receive an amount equal to twelve months of such executive’s salary, and certain Directors and managers would receive an amount equal to six months of such Director’s or managers fees or salaries, as applicable. In addition, the resolution passed provided for the immediate vesting of outstanding options, in the event of a change of control.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	694424	USD
CY2014	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	5655495	USD
CY2015	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	31853	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2015	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line method
CY2015	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	straight-line method
CY2014Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9707979	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12475919	USD
CY2014	us-gaap	Depreciation Depreciation	486726	USD
CY2015	us-gaap	Depreciation Depreciation	567679	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2014Q2	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture	5000000	USD
CY2014Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2015Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2014Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	121697	USD
CY2015Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	135874	USD
CY2014Q1	eltp	Unamortization Of Bond UnamortizationOfBond	232756	USD
CY2015Q1	eltp	Unamortization Of Bond UnamortizationOfBond	218579	USD
CY2014Q1	eltp	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	18870	USD
CY2015Q1	eltp	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	265165	USD
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18821	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	42524	USD
CY2014Q1	eltp	Equipment Financing Payable Non Current EquipmentFinancingPayableNonCurrent	-87574	USD
CY2015Q1	eltp	Equipment Financing Payable Non Current EquipmentFinancingPayableNonCurrent	-560338	USD
CY2014Q1	eltp	Lease Termination Costs Current LeaseTerminationCostsCurrent	0	USD
CY2015Q1	eltp	Lease Termination Costs Current LeaseTerminationCostsCurrent	0	USD
CY2014Q1	eltp	Lease Termination Costs Non Current LeaseTerminationCostsNonCurrent	24749	USD
CY2015Q1	eltp	Lease Termination Costs Non Current LeaseTerminationCostsNonCurrent	26275	USD
CY2014	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	69512	USD
CY2015	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	7937	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	295710	USD
CY2015	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2014	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	292611	USD
CY2015	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	3248	USD
CY2014	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	30835	USD
CY2015	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	7937	USD
CY2014	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	29668	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-3099	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-3248	USD
CY2014Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19813000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24547000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19813000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24547000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015	us-gaap	Valuation Allowance Commentary ValuationAllowanceCommentary	At March 31, 2015 and 2014, a 100% valuation allowance is provided
CY2015	eltp	Actual Lease Payments ActualLeasePayments	114321	USD
CY2014	eltp	Straight Line Deferred Rent Liability Adjustments StraightLineDeferredRentLiabilityAdjustments	-56518	USD
CY2014	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	37201848	shares
CY2015	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	12273057	shares
CY2015Q1	eltp	Warrants Outstanding WarrantsOutstanding	89870034	shares
CY2013Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.08
CY2014Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.06
CY2014	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice	0.09
CY2015	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice	0.07
CY2015Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.06
CY2015	eltp	Straight Line Deferred Rent Liability Adjustments StraightLineDeferredRentLiabilityAdjustments	-15409	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	18824	USD
CY2015Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	42524	USD
CY2015	eltp	Lease Initiation Date LeaseInitiationDate	2010-07-01
CY2015	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2016-12-31
CY2015	eltp	Operating Lease Description OperatingLeaseDescription	6 years with 2 tenant renewal options for 5 years each
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	33820	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	153430	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	203850	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	155169	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	359019	USD
CY2013Q1	eltp	Warrants Outstanding WarrantsOutstanding	139344939	shares
CY2014Q1	eltp	Warrants Outstanding WarrantsOutstanding	102143091	shares
CY2014	eltp	Actual Lease Payments ActualLeasePayments	83259	USD
CY2013Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	7862848	USD
CY2014	eltp	Derivative Liability Warrants Exercised In Period DerivativeLiabilityWarrantsExercisedInPeriod	-2757271	USD
CY2015	eltp	Derivative Liability Warrants Exercised In Period DerivativeLiabilityWarrantsExercisedInPeriod	1893300	USD
CY2014	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	32997869	USD
CY2015	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	-18447573	USD
CY2014	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	91796043	shares
CY2015	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	6060000	shares
CY2014	eltp	Derivative Liability Conversion Of Convertible Securities Change In Value DerivativeLiabilityConversionOfConvertibleSecuritiesChangeInValue	3237937	USD
CY2015	eltp	Derivative Liability Conversion Of Convertible Securities Change In Value DerivativeLiabilityConversionOfConvertibleSecuritiesChangeInValue	-303000	USD
CY2014	eltp	Adjustments To Additional Paid In Capital Conversion Of Convertible Securities AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities	9733270	USD
CY2015	eltp	Adjustments To Additional Paid In Capital Conversion Of Convertible Securities AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities	2266440	USD
CY2015Q1	eltp	Lease Termination Cost Payable LeaseTerminationCostPayable	50000	USD
CY2015Q1	us-gaap	Deferred Revenue DeferredRevenue	138889	USD
CY2015Q1	us-gaap	Advance Rent AdvanceRent	200000	USD
CY2014	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3175	shares
CY2015	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4.242	shares
CY2014	eltp	Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue	9825066	USD
CY2015	eltp	Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue Conversionofseriesbseriescandseriesepreferredsharesintocommonsharesvalue	2272500	USD
CY2014	eltp	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	174359	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	148917143	shares
CY2014	eltp	Incremental Common Shares Attributable To Warrant IncrementalCommonSharesAttributableToWarrant	15782718	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3939000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5435667	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2590000	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	308333	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	223334	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1195000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	160166	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7642167	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.18
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.54
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.07
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.31
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.08
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.12
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.60
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.18
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
CY2015	eltp	Stock Issued During Period Value Payment For Preferred Share Derivative Interest StockIssuedDuringPeriodValuePaymentForPreferredShareDerivativeInterest	0	USD
CY2014Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2016-12-31
CY2015	eltp	Lease Renewal Term LeaseRenewalTerm	P5Y
CY2013	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	110000	USD
CY2014	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	110000	USD
CY2013	us-gaap	Officers Compensation OfficersCompensation	368233	USD
CY2014	us-gaap	Officers Compensation OfficersCompensation	849737	USD
CY2015Q1	us-gaap	Officers Compensation OfficersCompensation	259750	USD
CY2014	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	202497	USD
CY2015	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	769400	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6029227	shares
CY2015	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	10000000	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.07
CY2015	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	14286	pure
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1000	USD
CY2015	eltp	Reversal Of Change In Fair Value Of Warrant Derivatives ReversalOfChangeInFairValueOfWarrantDerivatives	18447573	USD
CY2015	eltp	Reversal Of Change In Fair Value Of Preferred Share Derivatives ReversalOfChangeInFairValueOfPreferredShareDerivatives	25602370	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15117272	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	142857143	shares
CY2015	eltp	Incremental Common Shares Attributable To Warrant IncrementalCommonSharesAttributableToWarrant	22926029	shares
CY2015	eltp	Incremental Common Shares Attributable To Stock Options IncrementalCommonSharesAttributableToStockOptions	581020	shares
CY2015	us-gaap	Preferred Units Description PreferredUnitsDescription	a total of 1,351 shares of Series C Preferred Derivatives were exchanged for 1,351 shares of Series G Preferred Derivatives, with such Series G shares having the same value as the Series C shares being exchanged
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	600000	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	7953591	USD
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q2	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2014Q2	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670685	USD
CY2015Q1	eltp	Common Stock Traded Percent CommonStockTradedPercent	0.3	pure
CY2015Q1	eltp	Common Stock Weighted Average Price Percent CommonStockWeightedAveragePricePercent	0.97	pure

Files In Submission

Name	View Source	Status
0001144204-15-037217-index-headers.html	Edgar Link	pending
0001144204-15-037217-index.html	Edgar Link	pending
0001144204-15-037217.txt	Edgar Link	pending
0001144204-15-037217-xbrl.zip	Edgar Link	pending
eltp-20150331.xml	Edgar Link	completed
eltp-20150331.xsd	Edgar Link	pending
eltp-20150331_cal.xml	Edgar Link	unprocessable
eltp-20150331_def.xml	Edgar Link	unprocessable
eltp-20150331_lab.xml	Edgar Link	unprocessable
eltp-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v412306_10k.htm	Edgar Link	pending
v412306_ex10-85.htm	Edgar Link	pending
v412306_ex21.htm	Edgar Link	pending
v412306_ex23.htm	Edgar Link	pending
v412306_ex31-1.htm	Edgar Link	pending
v412306_ex31-2.htm	Edgar Link	pending
v412306_ex32-1.htm	Edgar Link	pending
v412306_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q1 Form 10-K Financial Statement

#000114420415037217 Filed on June 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q1 Form 10-K Financial Statement

#000114420415037217 Filed on June 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp